Financings In Brief: Andrx
Executive Summary
Andrx: Controlled-release drug delivery firm files for IPO of 2.2 mil. shares of common stock at $12 per share. Fort Lauderdale, Fla.-based Andrx says it will have 12.9 mil. shares outstanding after offering. There is a proposed over-allotment option of up to 330,000 shares. Oppenheimer & Co. and Gruntal & Co. are lead underwriters. Andrx is developing generic versions of Cardizem CD and Dilacor XR...